Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

New Halaven® (eribulin) and Lenvima® (lenvatinib) Data to be Presented at ESMO Demonstrate Continued Commitment to Eisai Oncology Portfolio

Posted on: 30 Sep 16

WOODCLIFF LAKE, N.J., Sept. 29, 2016 /PRNewswire/ -- Eisai Inc. announced today the presentation of seven abstracts featuring data on its cancer treatments at the European Society of Medical Oncology (ESMO) 2016 Congress. The abstracts highlight new results for the company's oncology agents, Halaven® (eribulin) and Lenvima® (lenvatinib), for investigational uses in difficult-to-treat cancers and provide new information about these agents across multiple tumor types. ESMO 2016 will be held from October 7-11 in Copenhagen, Denmark.

"The breadth of data to be presented at ESMO—from interim results from the Phase 1b portion of our trial evaluating lenvatinib in combination with the anti-PD-1 immunotherapy pembrolizumab to results from multiple sub-group analyses of registrational studies for eribulin and lenvatinib—underscores Eisai's commitment to researching and developing treatment options for patients with advanced cancers," said Alton Kremer, MD, PhD, Chief Clinical Officer and Chief Medical Officer, Oncology Business Group at Eisai. "We are continually looking to improve understanding of Eisai's oncology therapies, and through these data, we hope to support the medical community and the patients we both serve."

Presentations of note include:

Studies assessing the use of lenvatinib in combination with anti-PD-1 immunotherapy, including:

Initial results of an ongoing, open-label, multicenter, Phase 1b trial of lenvatinib in combination with pembrolizumab in patients with select solid tumors

A preclinical study analyzing the immune response in mouse tumor models to understand the anti-tumor effect and mechanism of action of the combination of lenvatinib and PD-1 blockade treatment in multiple cancer types

Sub-analyses of the Phase 3 SELECT study investigating responses in specific sites of metastasis (lung, liver, lymph nodes and bone) following treatment with lenvatinib for locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer

A preclinical study analyzing the role of FGFR and VEGFR signaling pathways in tumor growth and angiogenesis in human renal cell carcinoma xenografts treated with lenvatinib in combination with everolimus

For more information:

Editor's Details

Mike Wood

Last updated on: 30/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.